Faron Pharmaceuticals - Innovatiivisia lääketieteen ratkaisuja (Osa 2)

From what I’ve read about that CRO, the startup and the first few months are the most expensive time. We’re talking about millions in this case for the initial months. If this outfit is world-class, they would hardly jump on board if they doubted Faron’s solvency. Hopefully, this will be announced soon. At least it would significantly boost my confidence if it’s a good company (AI gave 3 options with justifications that stand out from the rest). Financing will surely be arranged for Faron, but an offering with its discounts and dilutions would be a major disappointment for me as a long-term owner. The schedule for partnering has certainly stretched, and spring will be here soon enough, which is when the purse starts to be empty again. In my mind, I’m weighing an offering and partnering as financing solutions on a 50/50 basis. This silence could be due to either option. Well, time will tell what happens…

12 Likes